

CURRICULUM VITA

Muhammad Aslam, MD

CURRENT POSITIONS

Director, Geriatric Psychiatry Fellowship Program VA Medical Center
Professor of Psychiatry, Department of Psychiatry & Behavioral Neuroscience

ADDRESSES

Department of Psychiatry & Behavioral Neuroscience
University of Cincinnati College of Medicine
260 Stetson Street, Suite 3200, PO Box 670559, Cincinnati, Ohio 45267-0559

Cincinnati VA Medical Center
3200 Vine Street, 116 A - Cincinnati, Ohio 45220

Telephone: (513) 558-1947

(513)- 861-3100 Ext:4186

Fax number: (513)-475-6967

E-mail: Muhammad.aslam@va.gov

aslamm@uc.edu

PROFESSIONAL EXPERIENCE

- 9/1/2019 – Effective Professor of Clinical Psychiatry, Department of Psychiatry,
University of Cincinnati College of Medicine/Cincinnati VAMA
- 7/1/2018 – Present Director, Geriatric Psychiatry Fellowship Training Program, VAMC
Cincinnati
- 5/2018 – 7/31/18 Acting Medical Director Mental Health Careline, VAMC Cincinnati
- 7/2010 – 6/2018 Director, Geriatric Psychiatry Fellowship Training Program, University of
Cincinnati College of Medicine / VAMC Cincinnati
- 2-2011 – 10/2016 Medical Director, Psychiatry Inpatient Geriatric Service, University
Hospital, Cincinnati, Ohio
- 8/2012 – 8/2019 Associate Professor of Clinical Psychiatry, Department of Psychiatry,
University of Cincinnati College of Medicine/Cincinnati VAMA
- 7/2002 – 8/2012 Assistant Professor of Clinical Psychiatry, Department of Psychiatry,
University of Cincinnati College of Medicine/Cincinnati VAMA
- 6/2009-8/30/2011 Medical Director, Outpatient Mental Health Division (OMHD),
Cincinnati VAMC

6/2002-11/2006	Supervisor / Consultant Long Term Care, Fort Thomas VAMC
6/2002-11/2006	Associate Director, Geriatric Psychiatry Fellowship Program Department of Psychiatry, University of Cincinnati/VAMC
7/2002 - 4/2006	Consultant Long Term Care & MHC, Mental Health Care Line, Chillicothe, VAMC
7/2001-6/2002	Geriatric Psychiatry Fellow, Department of Psychiatry, University of Cincinnati /VAMC
7/2000-6/2001	Chief Resident, Department of Psychiatry, University of Cincinnati
7/1997-6/2001	Resident, Department of Psychiatry, University of Cincinnati

RESEARCH EXPERIENCE

Department of Psychiatry, University of Cincinnati / VAMC

- 1) Sub-Investigator
Risperidone vs. Haldol safety and efficacy in chronic schizophrenic patients. (1996)
- 2) Sub-Investigator
A double blind, multi-center, placebo control study of Quetiapine vs. Chlorpromazine in treatment resistant schizophrenia.(1996)
- 3) Sub-Investigator
A double blind, placebo-controlled multi-center study of long-term efficacy of MK-0869 in the maintenance of antidepressant effects in geriatric outpatients with major depression. (Merck-2002)
- 4) Sub-Investigator NIMH study
A double-blind randomized study of Citalopram and cognitive behavioral social skills training augmentation of antipsychotic drugs in older patients with schizophrenia or schizoaffective disorder, depressed type. (2003-2005)
- 5) Sub-Investigator
An open-label, flexible-dose, 12 week clinical trial of the safety & efficacy of Escitalopram in the treatment of co-morbid anxiety & depression in the elderly. (Forest Pharmaceutical)
- 6) Co- Principal Investigator
A dose-ranging placebo-controlled study of SL 65.0155-10 at the doses of 0.5 mg, 2mg and 8 mg for 12 week in patients with mild to moderate Alzheimer's disease. (Sanofi Pharmaceutical)

- 7) Sub-Investigator
A 12-month, open label, flexible dosage study to evaluate the safety of Gabitril at dosages up to 16 mg/day in adults with chronic Post-Traumatic Stress Disorder. (Cephlon)
- 8) Sub-Investigator
An international, multi-center, randomized open label, large sample trial to compare cardiovascular safety of Ziprasidone and Olanzapine. Zodiac study (Pfizer)
- 9) Principal Investigator
A multi-center randomized, double-blind, placebo-controlled study of the effect of treatment with MPC-7869 on measures of cognitive function in subjects with mild to moderate dementia of Alzheimer's type. (Sanofi Pharmaceutical)
- 10) Sub-Investigator
A multi-center, randomized, double-blind, placebo-controlled study of Aripiprazole in the treatment of patients with bipolar I disorder with a major depressive episode. (Bristol-Meyers Squibb)
- 11) Principal Investigator
The SOURCE Study: Schizophrenia Outcomes-Utilization, Relapse, and Clinical Evaluation. A prospective 2-year observational study of patients with schizophrenia who initiate treatment with Risperidone long-acting microspheres. (Risperdal® CONSTA™ -Janssen Pharmaceutical -2006)
- 12) Principal Investigator
A multi-center, double-blind, flexible-dose, 6-month trial comparing the efficacy and safety of Asenapine with Olanzapine in stable subjects with predominant, persistent negative symptoms of schizophrenia.(Pfizer & Organon -2007)
- 13) Principal investigator
An open evaluation of the safety of Memantine in patients with moderate to severe Alzheimer's disease. (Forest Pharmaceutical -2007)
- 14) Principal investigator
An open-label extension study evaluating the safety of Memantine in patients with moderate to severe Alzheimer's disease. (Forest Pharmaceutical- 2009)
- 15) Sub-Investigator
A single arm evaluation of the safety of Paliperidone Extended-Release(ER)in subjects with schizophrenia or schizoaffective disorder with hepatic disease. (Ortho-McNeil Janssen)
- 16) Principal investigator

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy

17) Local Site (Principal) Investigator

*VA Cooperative Study # 572 "Genetics of functional disability in schizophrenia and bipolar illness". (2011- 2014) **Total Cost \$251,014***

18) Co-Local Site Investigator

*VA Cooperative Study #556: "The Effectiveness of rTMS in Depressed VA Patients". (2011- 2018) **Total Cost \$265,182***

19) Local Site (Principal) Investigator

*VA Cooperative Study #576 "Augmenting and Switching Treatments for Improving Depression Outcomes (VAST-D) (2011-2016) **Total Cost \$617,903***

20) Principal Investigator

"A randomized. Placebo Controlled, Parallel-Group, Double Blind Efficacy & Safety trial of MK-8931 IN Subjects with Mild to Moderate Alzheimer's Disease." (Merck Pharmaceutical 2012- Present)

21) Principal Investigator

"A randomized. Placebo Controlled, Parallel-Group, Double Blind Efficacy & Safety trial of MK-8931 IN Subjects with Mild Cognitive Impairment." (Merck Pharmaceutical 2014- Present)

22) Principal Investigator

"A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil. (LundBeck Pharmaceutical 2014-2018)

23) Principal Investigator

"An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease" (LundBeck Pharmaceutical 2014-2018)

24) Principal Investigator

"A phase 3, double-blind, randomized study of RVT- 101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease ". (Axovant Pharmaceutical 2015- 11/2016)

- 25) Local Site (Principal) Investigator
*VA Research & Development (R & D) funded study title "Precision Medicine in Mental Health Care - PRIME Care" (2017- Present) **Total Cost \$256,269***
- 26) Principal Investigator
BN29553: "A phase III, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal -to - Mild Alzheimer's Disease." (Roche Pharmaceutical 2017- Present)
- 27) Principal Investigator
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder (Allergan Pharmaceutical 2017- Present)
- 28) Principal Investigator
A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in patients with traumatic brain injury (TBI). (Avanir Pharmaceuticals, Inc 2018- Present)

Teaching & Speaking Experience

- 1) Lead & Introduce speakers for Geriatric Psychiatry monthly Case conference, Seminars and Journal clubs.
- 2) Lectured on yearly basis to 2nd and 3rd year psychiatry residents on geriatric psychopharmacology & Differential Diagnosis of Dementia.
- 3) Preceptor for 3rd year medical students at VA Medical Center Mental Health Clinic.
- 4) Presented on a regular basis for Department of Psychiatry & Behavioral Neuroscience Thursday conferences and grand rounds.
- 5) Guest speaker, State Wide Geriatric Medicine Conference, Cambridge, Ohio. (10/2006)
- 6) Guest speaker: monthly series for NAMI, Hamilton County Chapter. (8/2009)
- 7) Guest speaker at local church "Awareness of mental health and cultural issues" (11/2008)
- 8) Guest speaker at local church: "Awareness and burden of psychiatric disorders" (7/2010)

- 9) Symposium Chair: American Association of Geriatric Psychiatry Annual Meeting, held in San Antonio, TX, March 2011 Maintenance of Certification and the Performance in Practice Component: "Sample Tools for the Care of Patients with Depression"
- 10) Guest speaker Alois Alzheimer Foundation, Cincinnati, Ohio "An Evening of Hope and Celebration". (4/5/2013)
- 11) Guest speaker Mercy Neighborhood Ministries, Walnut hills Cincinnati, Ohio (8/29/2013)
- 12) Guest speaker Family & support Group, Deaconess hospital Cincinnati, Ohio (12/11/2013)
- 13) Overview of Alzheimer's Disease. R1 Didactics. Univ of Cincinnati, Dept. of Psychiatry & Behavioral Neuroscience, Cincinnati, OH, (11/2013)
- 14) Preceptor & Discussant resident Journal Club "Mild Cognitive Impairment as a Predictor of Falls in the Community Dwelling Older People" (12/8/2013)
- 15) Guest speaker Alois Alzheimer Center, Cincinnati, Ohio "Diagnosis & Management of Alzheimer dementia". (2/11/2014)
- 16) Geriatric Psychopharmacology. R2 Didactics. University of Cincinnati, Dept. of Psychiatry & Behavioral Neuroscience, Cincinnati, OH. (4/2014).
- 17) Overview of Dementia. MS II Didactics. University of Cincinnati, College of Medicine, Cincinnati, OH. (4/2014)
- 18) Guest speaker second Cincinnati VA Annual Mental Health Summit Overview of Geriatric Psychiatry Services. (9/2014)
- 19) Guest speaker UC mood disorder Center, Neuroscience Institute " Depression as We Age". (11/15/2014)
- 20) Guest panelist " Voice of America" International Urdu service discussion on Alzheimer dementia. (9/9/2014)
- 21) Guest speaker King Edward Medical University, Lahore Pakistan Dept. of Psychiatry 9th Annual Conference "An Update on Alzheimer Dementia". (1/2/2015)
- 22) Featured on WCPO Cincinnati local TV " Discussion on Alzheimer dementia". (1/8/2015)
- 23) Guest speaker Alois Alzheimer Center, Cincinnati, Ohio "Living with Alzheimer's Disease: The latest on Diagnosis, Treatment and Research". (2/10/2015)
- 24) Dept. of Psychiatry & Behavioral Neuroscience monthly Translational Research Seminar "BACE inhibition: A novel mechanism of action in treatment of Alzheimer's Dementia" (11/4/2015)

- 25) American- Pakistani Decent Physicians of North America (APPNA) Winter Meeting, Lahore, Pakistan “ Current & Emerging Therapies of Alzheimer’s Dementia” (12/18/2015)
- 26) Dept. of Psychiatry & Behavioral Neuroscience Geriatric Psychiatry Monthly Seminar “ Current & Emerging Therapies of Alzheimer’s Dementia” (2/16/2016)
- 27) Guest speaker “ The treatment of Depression in the Geriatric Population” at Zion Baptist Church, 630-Glenwood Ave, Cincinnati, Ohio (4/13/2016)
- 28) CME course presentations “Geriatric Psychopharmacology, Depression, Dementia and Delirium in the Geriatric Population”, Mental Health Services Springfield , Ohio (4/22/2016)
- 29) CEU course presentation “Living with Alzheimer Disease” The latest on Diagnosis and Research, Department of Social work Services , VA Medical Center, Cincinnati, Ohio (9/28/2016)
- 30) “Introduction and Recognition of Alzheimer’s & Other Dementia’s ” Mental Health Clinic Peer Support Group” Department VA Medical Center, Cincinnati, Ohio (7/17/2017)
- 31) Dept. of Psychiatry & Behavioral Neuroscience Geriatric Psychiatry Monthly Seminar “Depression in the Elderly” (8/15/2017)
- 32) Led Roundtable Discussion " Use of Tele-Geriatric Psychiatry: Benefits and Barriers". AAGP Annual Meeting in Honolulu (3/17/2018)
- 33) Dept. of Psychiatry & Behavioral Neuroscience Geriatric Psychiatry Monthly Case Conference (4/6/2018)
- 34) Symposium Chair: American Association of Geriatric Psychiatry Annual Meeting, Atlanta, GA, March 2019 Session Title: “Update on ABPN Geriatric Psychiatry Maintenance of Certification Program”.
- 35) Dept. of Psychiatry & Behavioral Neuroscience Geriatric Psychiatry Monthly Seminar “Relationship between schizophrenia and dementia” (3/19/2019)
- 36) Dept. of Psychiatry & Behavioral Neuroscience Geriatric Psychiatry Monthly Seminar “Enhancing Access to Geriatric Mental Health via Tele-Psychiatry” (10/15/2019)
- 37) Dept. of Psychiatry & Behavioral Neuroscience, Psychiatry Residents Monthly Journal Club lead discussant “Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer’s Dementia: Evidence From the CitAD Study” (10/17/2019)

PUBLICATIONS:

- 1) *Adherence - Views from the nursing perspective problems and solution. Resident & Staff Physician, September 2002.*
- 2) *Kasckow JW, Mulchahey JJ, Aslam M, Sabai M, Mohamed S. When and how to use SSRI's to treat late-life depression. Current Psychiatry 2:43-47, 2003.*
- 3) *An open-label, flexible-dose, 12-week clinical trial of the safety & efficacy of Escitalopram in the treatment of co-morbid anxiety & depression in the elderly. (AAGP Annual Meeting, San Diego, California. (March 2005).*
- 4) *Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose pilot trial. Mohamed S, Osatuke K, Aslam M, Kasckow J. American Journal of Geriatric Pharmacotherapy 4(3):201-9, (2006). PMID:[17062320](https://pubmed.ncbi.nlm.nih.gov/17062320/)*
- 5) *VA site investigator Contributor title "The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study": Rationale and design considerations. (August 2015- Psychiatry Research)*
Somaia Mohamed a,n, Gary R. Johnson b, Julia E. Vertrees c, Peter D. Guarino b,d, Kimberly Weingart e, Ilanit Tal Young e, Jean Yoon f, Theresa C. Gleason g, Katherine A. Kirkwood b, Amy M. Kilbourne g,h, Martha Gerrity i, Stephen Marder j, Kousick Biswas k, Paul Hicks l, Lori L. Davism, Peijun Chen n, Alexandra Mary Kelada e, Grant D. Huang o, D. Lawrence b, MaryLe Gwin b, Sidney Zisook e,
- 6) *Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment - The VAST-D Randomized Clinical Trial (Contributor author, JAMA. 2017;318(2):132-145, doi:10.1001/jama.2017.8036).*
- 7) *Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans- A Randomized Clinical Trial (contributor author, JAMA Psychiatry. doi:10.1001/jamapsychiatry.2018.1483 Published online June 27, 2018).*
- 8) *Vitamin D level predicts all-cause dementia D level a manuscript (19-0065-R) has been accepted in Nutrition and Healthy Aging. (7/8/2019).*

POSTER PRESENTATIONS:

- 1) *Dunsieth N, Nelson EB, Brusman-Lovins LA, Holcomb JL, Aslam M, Welge J, Roby D, Taylor P, Soutullo CA, McElroy SL. "Psychiatric features of 113 convicted male sex offenders." Poster session at the Association for the Treatment of*

SexAbusers, San Antonio, Texas, November, 2001.

- 2) *Dunsieth N, Nelson EB, Brusman-Lovins LA, Holcomb JL, Aslam M, Welge J, Roby D, Taylor P, Soutullo CA, McElroy SL. "Psychiatric features of 113 convicted male sex offenders." Presented at the 32"d Annual Meeting of the American Academy of Psychiatry and the Law, Boston, Massachusetts, October 27, 2001.*
- 3) *Jayanti V, Aslam M, Hufford J, Carroll B. Catatonia in the elderly. (APA Annual Meeting, Toronto, Canada May,2006).*
- 4) *Shah, A, Aslam M, "Ethics of Treatment of Sexual Aggression in Geriatric Psychiatric Patients" Annual Meeting of American College of Legal Medicine, New Orleans, LA February, 2012.*
- 5) *Shah, A, Aslam M, "Ethics of Treatment of Sexual Aggression in Geriatric Psychiatric Patients" Annual Meeting of American for Geriatric Psychiatry, Los Angeles, CA, March, 2013.*
- 6) *Shah, A, Aslam M, Rowe, C, Sabai M, Gray, L " Proposed Assessment of Depression in the Caregivers of Older Adults in a Home Health Setting" Annual Meeting of American for Geriatric Psychiatry , Los Angeles, CA, March, 2013.*
- 7) *Brown M, Roberts J, Purganan K, Sabai M, Aslam M, Beal M. Utilization of paliperidone serum concentrations to guide off-label paliperidone palmitate dosing decisions. College of Psychiatric and Neurologic Pharmacists. Phoenix, AZ, April, 2014.*

MANUSCRIPTS REVIEWED:

- 1) International Journal of Psychiatry in Medicine IJPM June , 2012.
- 2) Annals of Long- Term Care (ALTC January, 2013).
- 3) The Annals of Pharmacotherapy titled, "The Safety and Tolerability of Vortioxetine in the Treatment of patients with Major Depressive Disorder; Analysis of Data from Randomized Placebo-controlled Trials and Open-label Extension Studies", July 31, 2015
- 4) The Annals of Pharmacotherapy, reviewed manuscript (ID AOP-16-0010) titled "Risk of Cognitive Decline Associated with Paroxetine Use in Elderly Nursing Home Patients with Depression", January 13, 2016
- 5) The Annals of Pharmacotherapy reviewed manuscript (ID AOP-16-0327) titled "Amisulpride in Refractory Behavioral and Psychological Symptoms of Dementia", July 22, 2016
- 6) The Annals of Pharmacotherapy reviewed manuscript (ID AOP-16-0373) titled " The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing in Nursing Home Residents with Alzheimer's type Neurocognitive Disorder", August 20, 2016

7) The Annals of Pharmacotherapy reviewed Manuscript ID AOP-16-0534 Pimavanserin (Nuplazid): “The first medication approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis”. November 8, 2016

8) Journal of Psychiatry and Behavior Therapy Manuscript ID: PYBT - 101014
“Evaluation of the Psychological Morbidity among Pregnant Women in South Western Nigeria”
March 22/2018.

BOOK CHAPTER & REVIEW EXAMINATION:

- 1) Contributor Author Self-Assessment Examination American Association for Geriatric Psychiatry Annual Meeting (3/ 2015).
- 2) Section Editor & Author “ Geriatric Psychiatry Self-Assessment Program (GPSAP)”
Published. (7/2017
- 3) Contributor Author Self-Assessment Examination American Association for Geriatric Psychiatry Annual Meeting . (3/2016).
- 4) Contributor Author Self-Assessment Examination American Association for Geriatric Psychiatry Annual Meeting . (3/2017).
- 5) Contributor Author Self-Assessment Examination American Association for Geriatric Psychiatry Annual Meeting . (3/2018).
- 6) Selected International Models of Psychiatric Emergency Care: Pakistan (Co-author-
Submitted-9/14/2018 -pending publication)

EDUCATION

1993: MB,BS (MD): King Edward Medical College, Lahore Pakistan

Certification

USMLE Step 1: Sept, 1994

USMLE Step 2: Aug, 1995

ECFMG: Jan, 1996

USMLE Step 3: Jan, 2001

ABPN (Diplomate American Board of Psychiatry & Neurology- 6/2007) # 57503

ABPN (Diplomate American Board of Geriatric Psychiatry-5/2008) # 2834

ABPN (Diplomate American Board of Psychiatry & Neurology-recertified 4/2017) # 57503

ABPN (Diplomate American Board of Geriatric Psychiatry-recertified 4/2017) # 2834

DEA# BA 7343623

MEDICAL LICENSE& MEMBERSHIPS

March 2001- Present	State Medical Board of Ohio
May 1998- 2009	Member American Psychiatric Association
May 1998 - 2009	Member Ohio Psychiatric Association
Jan 1999 - Present	Member American Association of Geriatric Psychiatry
2004-2005	Member Geriatric Psychiatry Task Force VA VISN 10
2002-2006	Member Residency Training Committee, Department of Psychiatry & Behavioral Neuroscience.
2005 - 2012	Member VA EEO Advisory Board
2007 - 2009	Member Pharmacy & Therapeutic Committee VAMC
2009 – Present	Member American Association for Geriatric Psychiatry Education & Training Committee
2009 - Present	Member American Association for Geriatric Psychiatry CME Committee.
2009 - Present	Member Residency Program Evaluation Committee Department of Psychiatry & Behavioral Neuroscience.
2009 - Present	Member VAMC Peer Review Committee
2010 - Present	Member National Network of Depression (NNDC) Geriatric Mood Disorders Task Group
2012 - Present	Member Scientific Advisory Board, World Parkinson's Program
2013- 2014	Secretary Greater Cincinnati Tri-State Area Chapter of American- Pakistani Decent Physicians of North America (APPNA).
2014 - 2015	Member Admission Committee, University of Cincinnati College of Medicine.
2015- Present	Member Department of Psychiatry & Behavioral Neuroscience Re-appointment, Promotion & Tenure Committee
2015 - 2017	President Greater Cincinnati Tri-State Area Chapter of American- Pakistani Decent Physicians of North America (APPNA).
2015- Present	Member VA OIF/OEF Caregiver Review Committee
2015- Present	Member VA VISN 10 Dementia Steering Committee
2016- Present	Member Cincinnati VA Research & Development Committee
12/19-2016	Chair CME committee King Edward Medical College Alumni of North America (KEMCAANA) Winter meeting, King Edward Medical University, Lahore, Pakistan
2017-Present	Member Editorial Board- International Journal of Neurodegenerative Disorders
2017-Present	Member Editorial Board- Journal of Psychiatry and Behavior Therapy
2017-Present	Member Editorial Board- Journal of Ageing Science & Mental Health Studies (ASMHS)
10/26 -29/2017	Chair American- Pakistani Decent Physicians of North America (APPNA) Annual Fall Meeting, Cincinnati, Ohio.
11/17 – 3/1/2019	Co-Chair CME Committee American Association for Geriatric Psychiatry.
12/20 -2017	Co-Chair King Edward Medical College Alumni Association of

	North America (KEMCAANA) Annual Winter meeting, King Edward Medical University, Lahore, Pakistan.
10/2017 -Present	Member VISN 10 Complex Gero-Psych workgroup
3/20/18 - Present	Member Cincinnati VA CLC Complex Gero-Psych / Dementia Steering Committee.
9/02/18 - Present	Director Bi-annual Ongoing Professional Practice Evaluation for Cincinnati VA Medical Center Mental Health Careline Physicians.
2018- 2019	Treasurer King Edward Medical College Alumni Association of North America (KEMCAANA)
2019- 2020	Secretary King Edward Medical College Alumni of North America (KEMCAANA)
2020	President Elect- King Edward Medical College Alumni of North America (KEMCAANA)
3/4/19 – Present	Chair CME Committee American Association for Geriatric Psychiatry

HONORS & AWARDS

- 2000 Pfizer pharmaceutical: Resident of the Year
- 2002 Janssen pharmaceutical: Fellow of the Year
- 2015 “Top doctor in Metropolitan Cincinnati area” by Cincinnati Magazine.
- 2019 “Top doctor in Metropolitan Cincinnati area” by Cincinnati Magazine.

Personal

Health: Excellent
 Marital Status: Married
 Languages: Fluent written and spoken English & Urdu.
 Interest: Basketball, football, cricket, and tennis
 Citizenship: USA

References

Available upon request

